Article ID Journal Published Year Pages File Type
6185259 Gynecologic Oncology 2013 5 Pages PDF
Abstract
The escalating doses and cycles of intraperitoneal phIL-12/PPC when combined with carboplatin/docetaxel chemotherapy in recurrent ovarian cancer patients were well tolerated and did not appear to exacerbate the side effects or attenuate the efficacy of the chemotherapy treatment.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer
Authors
, , , , , ,